If You Invested in Bausch + Lomb Corporation (BLCO)

Bausch + Lomb Corporation (NYSE/TSX: BLCO) is a global eye health company in the ophthalmic goods manufacturing industry. The company describes its mission as helping people see better to live better around the world. It focuses on eye health products and services that span contact lenses, prescription products, over-the-counter options and surgical devices.

According to company disclosures and public statements, Bausch + Lomb operates across key areas of eye health, including vision care, surgical and pharmaceutical businesses. Its vision care segment includes contact lenses and ocular health products. The surgical segment includes intraocular lenses, equipment for cataract and vitreoretinal surgeries and related surgical instruments. The ophthalmic pharmaceuticals segment includes prescription eye care products that address different eye conditions. The company has stated that it offers more than 100 eye care prescription products.

Bausch + Lomb has indicated that it is one of the largest vision care companies in the United States and that it has built what it describes as the largest portfolio of eye care prescriptions in its space. The firm was previously a subsidiary of Bausch Health Companies Inc. and was spun off to become a publicly traded company. Its common shares trade on both the New York Stock Exchange and the Toronto Stock Exchange under the symbol BLCO, and it is incorporated in Canada.

Business segments and product focus

The company reports its operations in three primary segments:

• Vision Care – includes contact lenses and ocular health products. Within this segment, the company has highlighted brands such as Biotrue and Lumify in its ocular health portfolio.
• Surgical – includes intraocular lenses, equipment for cataract and vitreoretinal surgeries and surgical instruments used in eye surgery.
• Ophthalmic Pharmaceuticals – includes prescription eye care products such as Xipere, Vyzulta and Lotemax, which are used to address various eye-related conditions.

In its public communications, Bausch + Lomb emphasizes a long history in eye health, describing its evolution over nearly two centuries as it has adapted to changing patient and customer needs. The company also highlights a focus on research and development and on building a product pipeline across consumer eye care, pharmaceuticals, surgical technologies and contact lenses.

Eye health focus and partnerships

Bausch + Lomb regularly engages in partnerships and programs related to eye health conditions and awareness. For example, the company has announced an annual fundraising challenge with the Glaucoma Research Foundation during Glaucoma Awareness Month, matching donations up to a stated amount to support glaucoma research. It also sponsors an educational social media campaign with The Glaucoma Foundation that shares stories from glaucoma patients and advocates to highlight the impact of the disease and the importance of early detection.

The company’s communications describe glaucoma as a chronic, progressive disease and a leading cause of irreversible blindness in the United States. Through these collaborations, Bausch + Lomb positions itself as supporting both research and education aimed at improving outcomes for people affected by glaucoma.

Sustainability and recycling initiatives

Bausch + Lomb has also described sustainability-focused initiatives linked to its eye health products. In the United States, its ONE by ONE Recycling Program, created with TerraCycle, collects used contact lenses, blister packs, top foils, contact lens cases, small contact lens solution bottles and caps, single-dose eye drop vials, certain eye drop bottles and specific packaging components. Participating eye care practices collect these materials, which are then shipped to TerraCycle to be recycled and repurposed.

The company has reported that this program has collected hundreds of thousands of pounds of used contact lens, eye care and lens care materials in the United States, and that for qualifying shipments from registered practices a donation per pound is made to Optometry Giving Sight, a global initiative focused on preventing blindness and vision impairment. Bausch + Lomb has also launched the Every Contact Counts program in Canada, which similarly collects used contact lenses, blister packs and top foils for recycling.

In its sustainability communications, the company notes that it tracks impact initiatives against environmental metrics summarized as “FEWW” – fuel, energy, water and waste – and that each facility has annual goals related to these measures.

Capital structure and financing activities

Bausch + Lomb’s SEC filings describe several financing transactions. The company has entered into a credit and guaranty agreement and subsequent amendments that provide term loans and revolving credit facilities. For example, a third amendment to its credit agreement provided a new tranche of term loans maturing in 2031 and a new revolving credit facility, with proceeds used to refinance earlier term loans and repay borrowings under a prior revolving facility. A later fourth amendment provided replacement term loans, also maturing in 2031, to refinance existing term B loans.

The company has also reported issuing senior secured floating rate notes due 2031 through its subsidiaries, with net proceeds used together with term loans to refinance existing debt and repay outstanding borrowings under its revolving credit facility. These transactions are detailed in Form 8-K filings and associated indentures and amendments.

Stock listing and regulatory reporting

Bausch + Lomb files periodic and current reports with the U.S. Securities and Exchange Commission and with Canadian securities regulators. These include Form 10-K annual reports, Form 10-Q quarterly reports and Form 8-K current reports describing material events such as financing transactions, board changes, executive compensation arrangements, and financial results for specific quarters. The company’s common shares are registered under Section 12(b) of the Securities Exchange Act of 1934 and trade on the New York Stock Exchange and the Toronto Stock Exchange under the symbol BLCO.

Research, pipeline and strategic focus

In its investor communications, Bausch + Lomb has described a product pipeline spanning consumer eye care, pharmaceuticals, surgical devices and contact lenses. It has highlighted clinical-stage programs and potential new products in areas such as dry eye, glaucoma, ocular surface pain, age-related macular degeneration and contact lens materials. The company has also discussed a multi-year plan targeting revenue growth and margin expansion, and has referenced the use of technologies, including artificial intelligence, in its operations and transformation efforts.

While specific financial targets and timelines are subject to change and are presented as forward-looking statements in company materials, these disclosures indicate that Bausch + Lomb’s strategy centers on expanding its eye health portfolio, advancing its pipeline and focusing on operational efficiency.

Role in the ophthalmic goods manufacturing sector

Within the ophthalmic goods manufacturing and broader eye health sector, Bausch + Lomb positions itself as a global eye health company with activities that cover consumer eye care, prescription pharmaceuticals, surgical products and vision correction. Its combination of branded contact lenses, ocular health products, prescription medicines and surgical technologies, along with sustainability and disease-awareness initiatives, defines its role in the market as presented in its public statements and regulatory filings.